TerminatedNot Applicable

Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Stopped: inclusion number not reached during the period

France296 participantsStarted 2021-01-20

Plain-language summary

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patient case: * Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease * With confirmed COVID-19 infection (at least one month prior to study inclusion) * Study information given to the patient * Patient affiliated to social security Patient control: * Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease. * Not having had a confirmed COVID-19 infection * Study information given to the patient * Patient affiliated to social security Exclusion Criteria: * Opposition to participation in the study by the patient and/or his legal representative * Adult patient not able to understand the implications and rules of the study * Protected adults under guardianship or curatorship

What they're measuring

Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID

Timeframe: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Trial details

NCT IDNCT04510467

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-05-19